[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol; 2006 May;1(4):289-95
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
  • INTRODUCTION: Extrapleural pneumonectomy (EPP) and adjuvant high-dose radiation therapy (RT) are associated with a median survival of 3 years in early-stage malignant pleural mesothelioma (MPM) but of less than 1 year in locally advanced disease.
  • We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival.
  • Induction therapy was four cycles of gemcitabine and cisplatin.
  • Patients without disease progression by computed tomography underwent EPP followed by adjuvant hemithoracic RT (54 cGy).
  • Histology was epithelioid in 14 patients and mixed or sarcomatoid five patients.
  • Nineteen patients received induction chemotherapy.
  • Response to induction therapy was complete in zero patients, partial in five patients, stable disease in six patients, and progression of disease in eight patients.
  • CONCLUSION: Induction chemotherapy with gemcitabine and cisplatin followed by EPP and adjuvant RT for locally advanced MPM is feasible and leads to a better median overall survival than that previously reported with EPP and RT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409872.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Tanzi S, Tiseo M, Internullo E, Cacciani G, Capra R, Carbognani P, Rusca M, Rindi G, Ardizzoni A: Localized malignant pleural mesothelioma: report of two cases. J Thorac Oncol; 2009 Aug;4(8):1038-40
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized malignant pleural mesothelioma: report of two cases.
  • Localized malignant pleural mesothelioma is very rare tumor disease.
  • There are sporadic reports in the literature showing that this entity has a different biologic behavior compared with diffuse pleural mesothelioma.
  • We report two cases of radically resected localized pleural malignant mesothelioma, with a previous history of asbestos exposure.
  • Both cases showed a microscopic and immunohistochemical findings of malignant mesothelioma, biphasic and sarcomatoid lympho-histiocitoid variant type, respectively, without evidence of diffuse pleural spread.
  • The first is very peculiar case of bilateral localized malignant pleural mesothelioma with complete response to chemotherapy and localized late recurrence, radically resected and treated with adjuvant radiotherapy.
  • Both cases demonstrate that the localized malignant mesothelioma should be distinguished from diffuse form and that complete resection is associated with good prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633479.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ: Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg; 2010 Aug;140(2):352-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
  • OBJECTIVE: Optimizing the multimodality treatment of malignant pleural mesothelioma depends on many factors including an adequate chemotherapeutic response.
  • Currently, chemotherapy regimens for patients with mesothelioma are empirically selected.
  • In vitro chemotherapy resistance in human mesothelioma has not been reported.
  • Our goal was to determine the prevalence of drug resistance in a large sample of malignant pleural mesothelioma using a commercially available assay.
  • METHODS: Tumors specimens (n = 203) were cultured for analysis of chemoresistance using the extreme drug resistance assay.
  • Each specimen was tested with 3 drugs: cisplatin, gemcitabine, and vinorelbine.
  • Drug resistance was characterized as low, intermediate, or extreme.
  • Forty-four (26%) patients received neoadjuvant chemotherapy before sampling and testing.
  • The distribution of histopathologic cell types was epithelial (103; 61%), mixed (57; 34%), and sarcomatoid (8; 5%).
  • RESULTS: A significant proportion of tumors had extreme/intermediate drug resistance to cisplatin (27%), gemcitabine (31%), or vinorelbine (59%).
  • Nineteen tumors (11%) had extreme/intermediate resistance to all 3 drugs.
  • No significant differences in chemoresistance were found in tumors of patients who had received neoadjuvant chemotherapy compared with those who had not.
  • CONCLUSIONS: The feasibility of performing off-site in vitro drug resistance assays on resected malignant mesothelioma specimens is reported.
  • A significant proportion of mesothelioma tumors exhibited extreme/intermediate resistance to cisplatin, gemcitabine, or vinorelbine.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Cisplatin / pharmacology. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Feasibility Studies. Humans. Middle Aged. Neoadjuvant Therapy. Patient Selection. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653100.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


Advertisement
4. Zellos LS, Sugarbaker DJ: Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Williston Park); 2002 Jul;16(7):907-13; discussion 916-7, 919-20, 925
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse malignant mesothelioma of the pleural space and its management.
  • Diffuse malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura that is usually caused by exposure to asbestos.
  • Difficulties in diagnosis, staging, and treatment set this disease apartfrom other malignancies.
  • The variable clinical presentation and problems in establishing a definite histopathologic diagnosis result in significant delays in treatment.
  • Three histologic subtypes of the disease are described in this review: epithelial, sarcomatous, and mixed histologies.
  • The Butchart, International Mesothelioma Interest Group, and Brigham staging systems are the most commonly used staging systems.
  • The disease's natural history involves aggressive local growth, invasion of vital mediastinal structures, and death within 4 to 12 months without treatment.
  • Single-modality therapy of any kind has failed to substantially alter this natural history.
  • Aggressive, multimodality regimens that include surgery, radiation, and chemotherapy have resulted in improved survival in properly selected patients.
  • However, innovative therapies are still needed to prolong survival in patients with early and advanced disease.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / therapy. Pleural Neoplasms / pathology. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12164558.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


5. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 May;3(5):499-504
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality treatment of malignant pleural mesothelioma.
  • INTRODUCTION: Multimodality treatment has achieved significant success in local control and treatment of early-stage malignant pleural mesothelioma patients.
  • METHODS: We have instituted a trimodality treatment protocol consisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy) hemithoracic irradiation, and platin-based chemotherapy in a multi-institutional setting.
  • Preoperative pulmonary function tests, echocardiogram, chest computed tomography, and magnetic resonance imaging scans were performed in all patients.
  • Histology was epithelial in 17, mixed in 2, and sarcomatoid in 1.
  • Twelve patients completed all three treatments.
  • CONCLUSIONS: Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449002.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Antman K, Hassan R, Eisner M, Ries LA, Edwards BK: Update on malignant mesothelioma. Oncology (Williston Park); 2005 Sep;19(10):1301-9; discussion 1309-10, 1313-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on malignant mesothelioma.
  • The histology of about half of mesotheliomas is epithelial (tubular papillary), with the remainder sarcomatous or mixed.
  • Multicystic mesotheliomas and well-differentiated papillary mesotheliomas are associated with long survival in the absence of treatment and should be excluded from clinical trials intended for the usual rapidly lethal histologic variants of the disease.
  • Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / diagnosis. Mesothelioma / epidemiology. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Asbestos / adverse effects. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / therapeutic use. Heart Neoplasms / pathology. Humans. Incidence. Male. Neoplasm Staging. Peritoneal Neoplasms / pathology. Platinum Compounds / administration & dosage. Platinum Compounds / therapeutic use. Pleural Neoplasms / pathology. Prognosis. Quality of Life / psychology. Survival Analysis. Testicular Neoplasms / pathology. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285225.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Platinum Compounds; 1332-21-4 / Asbestos
  •  go-up   go-down


7. Ak G, Metintas S, Metintas M, Yildirim H, Erginel S, Kurt E, Alatas F, Cadirci O: Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol; 2009 Nov;4(11):1425-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
  • OBJECTIVES: In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment schedules, including those treated with best supportive care, chemotherapy, and multimodality therapy.
  • The patients were classified into three groups according to their treatment schedules: the best supportive care group, the chemotherapy group, and the multimodality therapy group.
  • However, the effectiveness of treatment schedules as a prognostic factor was not evaluated in this study.
  • RESULTS: After adjusting for therapy in a Cox model, a Karnofsky Performance Status (KPS) < or = 70, a right side tumor, serum lactate dehydrogenase >500 IU(-1), a nonepithelial subtype, and stage 3 to 4 disease were determined by multivariate analyses to be unfavorable prognostic factors for all the patients.
  • A KPS < or = 70, serum lactate dehydrogenase >500 IU(-1), a nonepithelial subtype, and stage 3 to 4 disease were associated with a poor prognosis for the best supportive care group.
  • The single unfavorable prognostic factor for the chemotherapy group was a KPS < or = 70.
  • A right side tumor and a nonepithelial subtype were associated with a poor prognosis for the multimodality therapy group.
  • CONCLUSIONS: The patients with an epithelial subtype, a good KPS, and an early-stage tumor had a good prognosis, even if they did not receive any treatment.
  • The only prognostic factor for the chemotherapy group was KPS.
  • A mixed subtype and a right side tumor were unfavorable prognostic factors for the multimodality therapy group.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate / trends. Turkey / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752758.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M: Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol; 2007 Oct;14(10):2790-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  • BACKGROUND: Multicystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy.
  • The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.
  • One patient underwent the procedure twice due to locoregional MPM recurrence.
  • Transition of typical WDPPM to malignant biphasic mesothelioma was documented in one patient who died of disease progression following incomplete cytoreduction and HIPEC.
  • Following multimodality treatment, 5-year overall and progression-free survival were 90.0% (standard error = 9.0) and 79.7% (11.9), respectively.
  • Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma, Cystic / drug therapy. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Reoperation

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17661150.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, Norton A, Ashley S, Smith IE: The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol; 2004 Sep;15(9):1406-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
  • BACKGROUND: With the rising incidence of malignant mesothelioma (MM), it is important to optimise treatment to control symptoms, maintain quality of life and, if possible, prolong life.
  • We have analysed prospectively collected data to evaluate a frequently used palliative chemotherapy regimen.
  • PATIENTS AND METHODS: Between October 1986 and May 2002 all patients with inoperable pleural mesothelioma were considered for treatment with MVP (mitomycin C 8 mg/m2 every 6 weeks, vinblastine 6 mg/m2 every 3 weeks and cisplatin 50 mg/m2 every 3 weeks) chemotherapy.
  • Symptoms were assessed by physician assessment at baseline and after each cycle of chemotherapy.
  • RESULTS: One hundred and fifty patients were treated with MVP for mesothelioma.
  • Poor prognostic factors in univariate analysis included poor PS, weight loss, mixed or sarcomatoid histology, low haemoglobin and high white blood cell count.
  • CONCLUSIONS: Palliation of symptoms in MM is achievable with current cisplatin-based treatments.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15319247.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN: Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol; 2008 Feb;31(1):49-54
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
  • OBJECTIVE: We report a single-institution Phase I or II trial of surgical debulking, intraperitoneal chemotherapy, and immunotherapy followed by whole abdominal radiotherapy in patients with malignant peritoneal mesothelioma.
  • METHODS: Between 1997 and 2000, 27 patients with malignant peritoneal mesothelioma were enrolled: 23 with epithelial subtype and 4 with sarcomatoid or mixed subtype.
  • The treatment regimen consisted of surgical debulking followed by 4 intraperitoneal courses of cisplatin alternating with 4 courses of doxorubicin, 4 doses of intraperitoneal gamma interferon, a second laparotomy with resection of residual disease plus intraoperative intraperitoneal mitomycin and cisplatin heated to 41 degrees C, and finally whole abdominal radiotherapy.
  • RESULTS: The median overall survival was 70 months with a 3-year survival of 67% (95% confidence interval, 46%-81%).
  • Fourteen patients have died of their disease with a median time to death of 17 months (range, 0.4-71 months) after consenting to treatment.
  • Seven patients are alive without evidence of disease with a median follow-up of 90 months (range, 71-110 months), and 6 are alive with disease with a median follow-up of 86 months (range, 70-106 months).
  • CONCLUSION: Based on the results of this study, intensive multimodality therapy appears feasible and effective in this group of patients.
  • [MeSH-major] Abdominal Neoplasms / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Mesothelioma / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Injections, Intraperitoneal. Male. Middle Aged. Mitomycin / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376228.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Singhal S, Kaiser LR: Malignant mesothelioma: options for management. Surg Clin North Am; 2002 Aug;82(4):797-831
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: options for management.
  • In the past, there has been a tendency to think of diffuse malignant pleural mesothelioma as one disease in therapeutic terms, regardless of histological type and tumor stage.
  • This does not happen with other tumors, yet it is equally illogical and inappropriate in mesothelioma.
  • As with other tumors, early diagnosis-while the disease is still in stage I, or even at an in situ stage-must be the goal so that therapy can be maximized, particularly if immunotherapy or gene therapy is to be used.
  • Patients with pure epithelial mesothelioma have a better prognosis and respond better to trimodality therapy.
  • Stage I patients who meet fitness criteria should be offered the option of radical surgery in combination with chemotherapy and radiotherapy.
  • Further research is required to determine the optimum neoadjuvant and adjuvant modalities, particularly the timing of individual drugs, use of hyperthermia, and route of administration.
  • The place of immunotherapy and gene therapy as adjunctive treatments also remains to be defined.
  • For example, it may be possible to reduce tumor bulk and perhaps downstage the disease with immunotherapy before radical surgery, if treatment is started early enough.
  • Gene therapy may have a role either preoperatively or in destroying the microscopic disease that remains after radical surgery.
  • These and other combinations of treatment need to be tested in well-designed clinical trials, probably on a multicenter basis (to enroll a sufficient number of patients).
  • Finding the means to improve treatment for sarcomatous and mixed histology mesothelioma remains a challenge.
  • At present, radical surgery does not seem worthwhile for these patients when combined with currently employed chemotherapy and radiotherapy; however, chemotherapy combinations used for treating other sarcomas need to be evaluated as adjunctive therapy before radical surgery is abandoned altogether as a mode of treatment.
  • A collaborative approach involving thoracic surgeons, basic scientists and oncologists, and physicians with experience in treating mesothelioma is essential.
  • Despite its increasing frequency, mesothelioma is still a relatively rare tumor, so treatment should be concentrated in relatively few supraregional centers to maximize expertise and allow innovative treatment combinations to be implemented with the greatest chance of success.
  • Evaluation of new therapeutic approaches will be achieved more rapidly if these supraregional centers collaborate in multicenter trials.
  • The nihilistic approach of simply waiting until the mesothelioma epidemic eventually begins to decline spontaneously in 20 or 30 years is untenable in view of the hundreds of thousands of deaths that will result if no effective treatment is found.
  • [MeSH-major] Lung Neoplasms / therapy. Mesothelioma / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12472131.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 189
  •  go-up   go-down


12. Khadse P, Prabhash K, Pramesh CS, Chaturvedi P, Shet T: Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma. Diagn Cytopathol; 2009 Sep;37(9):680-5
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
  • Malignant mixed tumor of the parotid is known to have odd sites for metastases.
  • We describe the fine-needle aspiration cytology (FNAC) findings of pleural metastasis from a malignant mixed tumor misdiagnosed as a mesothelioma on cytology at the onset.A 47-year-old man presented to us with breathlessness and a massive pleural effusion with pleural-based nodules.
  • These cells in contrast to the usual mesothelial cells were not arranged in sheets but rather were huddled in places and formed a pseudoacinar pattern and blended with the myxoid substance.After the diagnosis of a mesothelioma, patient received pemetrexed and cisplatin based chemotherapy with partial response.
  • While on chemotherapy tumor recurred at the primary site in parotid and was confirmed to be a carcinosarcoma on a FNAC and biopsy.To conclude, pleural metastases from a true malignant mixed tumor of the parotid gland can be misdiagnosed as mesothelioma and could occur in the absence of uncontrolled disease at primary site.
  • Both mesotheliomas and pleomorphic adenomas metastatic to the pleura are biphasic tumors, but in a patient with history of pleomorphic adenoma, the latter should be kept as a foremost possibility.
  • [MeSH-major] Carcinosarcoma / secondary. Mesothelioma / pathology. Neoplasms, Complex and Mixed / secondary. Parotid Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Diagnosis, Differential. Diagnostic Errors. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pemetrexed. Pleural Effusion, Malignant / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373913.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Katayam N, Tokuda A, Nakatsumi Y, Oribe Y, Fujimura M: [A case of malignant mesothelioma presenting with recurrent pneumothorax]. Nihon Kokyuki Gakkai Zasshi; 2006 Nov;44(11):807-11
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant mesothelioma presenting with recurrent pneumothorax].
  • Although pneumothorax was treated successfully, increased pleural effusion, pleural thickening and subcutaneal tumor at the thoracic drainage suture site developed.
  • The histological examination of the biopsied subcutaneous tumor showed mixed type malignant pleural mesothelioma.
  • Chemotherapy with gemcitabine and vinorelbine could not control the progression.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pneumothorax / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Disease Progression. Fatal Outcome. Humans. Male. Picibanil / therapeutic use. Recurrence

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144577.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 39325-01-4 / Picibanil
  •  go-up   go-down


14. Nascimben O, Pagan V, Paccagnella A, Pizzi G: Surgery alone or in a multi-modality approach in the management of patients (pts) with Malignant Pleurant Mesothelioma (MPM): A 15-years experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):7197

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery alone or in a multi-modality approach in the management of patients (pts) with Malignant Pleurant Mesothelioma (MPM): A 15-years experience.
  • : 7197 Background: The role of surgery, chemotherapy (CT) and radiotherapy (RT) in MPM remain controversial.
  • We retrospectively reviewed all the pts with MPM referred to our Hospital between 1988 and 2003 and analysed the survival (S) by prognostic factors and modalities of treatment.
  • METHODS: 147 pts (M/F =117/30; median age =63) had histologically confirmed diagnosis of MPM (epithelial =100, mixed =23, sarcomatoid =13, not definable =11).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Janne PA, Obasaju C, Simon G, Taub R, Kelly K, Fidias P, Bloss LP, Kindler HL: A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).
  • Treatment consisted of gemcitabine 1250 mg/m2 on days 1 and 8, with pemetrexed 500mg/m2 on day 8, followed by gemcitabine, every 21 days for a total of 6 cycles or until progressive disease.
  • Pathologic diagnosis included epithelial 68.3%, mixed 12.2%, sarcomatoid 7.3%, and unclassified/other 12.2%.
  • Early response data is promising and time-to-event, updated response, and survival information on all 53 patients will be forthcoming.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016122.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Brechot JM, Morère JF, Des Guetz G, Chouhania K, Breau JL: Chemotherapy with gemcitabine and oxaliplatin in 13 malignant pleural mesothelioma (MPM): A monocenter experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):7250

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with gemcitabine and oxaliplatin in 13 malignant pleural mesothelioma (MPM): A monocenter experience.
  • This chemotherapy has been administered in clinical practice in our department for 2 years.
  • RESULTS: 13 pts (9 males, 4 females), mean age 62y (50-74), PS 0-1 12 pts, PS 2 1 pt, with a MPM diagnosed by pleuroscopy (9), thoracotomy (1) or blind pleural biopsy (3), with epithelial (4), mixed (4) and unspecified (5) histological subtype, all stage III or IV, received as outpatient treatment an association of gemcitabine 1000mg/m<sup>2</sup> D1 and oxaliplatin 100mg/m<sup>2</sup> D2 every 2 weeks with a mean of 8 cycles.
  • Median time to progression (TTP) was 7,5 months.
  • In 5 cases, treatment was discontinued because of non hematologic toxicities (allergia grade 3 in 2 pts at the 6<sup>th</sup> and 7<sup>th</sup>cycles, peripheral neurotoxicity in 3 pts (at the 6<sup>th</sup> and 10<sup>th</sup> cycles).
  • CONCLUSION: GEMOX is a well tolerated and active chemotherapy regimen in MPM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Van Schil PE, Baas P, Gaafar R, Maat AP, van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, Van Meerbeeck J, EORTC Lung Cancer Group: Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol; 2009 May 20;27(15_suppl):7509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031).
  • : 7509 Background: MPM is a highly lethal disease and the role of EPP in the treatment of early stage, potentially resectable MPM remains controversial.
  • EORTC 08031 phase II trial investigated the feasibility of trimodality therapy (TMT) consisting of ICT followed by EPP and PORT.
  • Primary endpoint was "success of treatment" defined as a patient receiving the full protocol treatment, still alive 90 days after end of treatment without progression and without grade (G) 3-4 toxicity.
  • Median age was 57 years (range 26-67), M/F 46/12, all proven MPM (31 epithelial, 18 mixed, 9 other).
  • After median follow- up of 19.3 months (mos) median overall survival time was 18.4 mos (95% CI 14.8-NR) and median progression-free survival was 13.9 mos (95% CI 10.9-17.1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963479.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Flores RM, Krug L, Rosenzweig KE, Vincent A, Akhurst T, Heelan R, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7193

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM).
  • : 7193 Background: Approximately 25% of patients (pts) with malignant pleural mesothelioma (MPM) prove unresectable at surgery and the median survival of stage III MPM is <12 months even after complete resection by extrapleural pneumonectomy (EPP).
  • Improving chemotherapy for MPM led us to test induction chemotherapy followed by EPP and adjuvant hemithoracic radiation (RT) for locally advanced MPM to assess feasibility and estimate survival.
  • Induction therapy was: gemcitabine (1250mg/m<sup>2</sup>days 1, 8) and cisplatin (75mg/m<sup>2</sup>day 8) x 2-4 cycles.
  • Pts underwent EPP 3-5 weeks after induction therapy, then 54 Gy RT 4-6 weeks postop.
  • Chemotherapy response was assessed by RECIST criteria.
  • RESULTS: 21 pts (15 men, median age = 60 years) were consented to study, 19 received chemotherapy.
  • MPM histology was epithelial = 14, mixed or sarcomatoid =5.
  • 10 pts completed 4 chemotherapy cycles, while 9 received 1-2 cycles.
  • This experience supports additional studies of induction and multimodality therapy, especially with regimens such as cisplatin and pemtrexed which may be better tolerated and more effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Manente P, Colaut F, Toniolo L, Vicario G, Sartor L, Bortolin M, Visentin P, Scapinello C, Sartori CA: Are you sure to definitely rule out pleurecomy/decortication plus chemotherapy from treatment of malignant pleural mesothelioma? Our experience with 40 cases. J Clin Oncol; 2004 Jul 15;22(14_suppl):7320

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are you sure to definitely rule out pleurecomy/decortication plus chemotherapy from treatment of malignant pleural mesothelioma? Our experience with 40 cases.
  • METHODS: Since 1985 to 2002 40pts with MPM were submitted pleurectomy/decortication combined to intracavitary chemotherapy.Until 1994 intracavitary chemotherapy consisted of Cisplatinum + Ara C(18 pts treated).
  • HISTOLOGY: 22 epithelia subtype,11 mixed,7 sarcomatous.
  • PS: all pts were<or=to 2 according ECOG scale.25 pts received systemic chemotherapy:16 pts Adryamicin and Mytomicin until 1994.4 pts Carboplatin and IFN alfa since 1995 to 1996.Successively 5 pts received Carboplatin and Gemcitabin.15 pts didn't receive systemic chemotherapy owing to comorbidities.
  • Kaplan-Meier method demonstrated 2ys and 3-ys overall survival was respectively 28% and 17%.After 2ys from intervention only 14% of pts had no PD.Histology has been a significant (p=0.047) prognostic factor for survival but not for PD.After 2ys from intervention 20% of pts with epithelial subtype and 10% of pts with mixed histology had PD, while sarcomatous pts had PD after only 8 mos from intervention.T was not a significant prognostic factor even if 54% of Tla/1b pts (24 pts) had PD after 6 mos from intervention,while 65% of T2/T3/T4 pts (16 pts) had PD before 6 mos yet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Melloni G, Puglisi A, Ferraroli GM, Carretta A, Ceresoli G, Calori G, Zannini P: [Treatment of malignant pleural mesothelioma]. Minerva Chir; 2001 Jun;56(3):243-50
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant pleural mesothelioma].
  • [Transliterated title] Il trattamento del mesotelioma pleurico maligno.
  • BACKGROUND: In this study all patients observed between January 1993 and October 1997 with malignant pleural mesothelioma (MPM) have been analyzed in order to describe the impact of treatment modality on survival.
  • In 34 cases the histotype was epithelial, in 4 sarcomatoid, in 4 mixed, in 3 desmoplastic, and in 11 not specified.
  • Four treatment modalities were identified:.
  • 2) Chemotherapy = 19 patients;.
  • 3) Surgery+Chemo-therapy = 8 patients;.
  • 2) Chemotherapy = 7.5 months;.
  • 3) Surgery+Chemotherapy = 12 months;.
  • Using univariate analysis, 8 prognostic factors were studied (age, sex, asbestos exposure, side, histotype, performance status, stage, treatment).
  • Among these, only the stage and the performance status had shown a prognostic value on survival (p<0.05), while the treatment modality had not significantly influenced the prognosis.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11423790.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 32
  •  go-up   go-down


21. Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batirel HF, Sivrikoz C, Metintas S, Dundar E: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma. Lung Cancer; 2008 Aug;61(2):255-61
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.
  • In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed.
  • Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy.
  • The LD appearance time in supportive care is short.
  • The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response.
  • LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low.
  • The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.
  • [MeSH-major] Mesothelioma / pathology. Neoplasm Recurrence, Local. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Survival Analysis. Thoracotomy / adverse effects. Thoracotomy / mortality

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304688.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


22. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E: Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer; 2001 Nov;34(2):279-87
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
  • One-hundred and twenty-one cases of malignant pleural mesothelioma (MPM) seen between 1986 and 1999 at the authors' Institution were reviewed.
  • Histotype was epithelial in 88 patients (73%), sarcomatous in 21 (17%) and mixed in 12 (10%).
  • Ninety-one patients received a treatment (38 palliative pleurectomy and no further therapy, 16 palliative pleurectomy followed by chemotherapy, 37 chemotherapy alone), while 30 were referred to supportive care only.
  • Univariate analysis of subgroups showed that poor performance status (PS), non-epithelial histotype, Butchart stage>I and International Mesothelioma Interest Group (IMIG) stage>I were individually associated with lower survival.
  • Patients receiving any therapy survived longer than patients treated with supportive care only (P=0.0004).
  • Treatment modality had an independent prognostic value (P=0.00005), with a survival advantage for patients receiving surgery and adjuvant chemotherapy.
  • Multivariate analysis confirmed the independent prognostic value of PS (P=0.001; HR=2.48) and treatment modality (P=0.003; HR=1.38).
  • The prognostic role of PS (P=0.02) and treatment modality (P=0.01) was confirmed in the subset of patients with epithelial histology.
  • On the contrary, therapy had no impact on survival in patients with sarcomatoid MPM (P=0.74).
  • Despite the predicted bias of a retrospective non-randomized evaluation of treatment-related factors, patients with good PS and epithelial histology seemed to have a survival benefit from surgery or multimodality therapy, as opposite to patients with poor PS or non-epithelial histotype.
  • However, these results must be confirmed in a larger prospective trial with uniform treatment.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679187.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


23. Allen AM, Den R, Wong JS, Zurakowski D, Soto R, Jänne PA, Zellos L, Bueno R, Sugarbaker DJ, Baldini EH: Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1366-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
  • PURPOSE: Extrapleural pneumonectomy (EPP) is an effective treatment of malignant pleural mesothelioma.
  • We compared the outcomes after moderate-dose hemithoracic radiotherapy (MDRT) and high-dose hemithoracic RT (HDRT) after EPP for malignant pleural mesothelioma.
  • Between 1994 and 2002, MDRT, including 30 Gy to the hemithorax, 40 Gy to the mediastinum, and boosts to positive margins or nodes to 54 Gy, was given, generally with concurrent chemotherapy.
  • In 2003, HDRT to 54 Gy with a matched photon/electron technique was given, with sequential chemotherapy.
  • The histologic type was epithelial in 25 patients (64%) and mixed or sarcomatoid in 14 patients (36%).
  • The median time to distant failure (DF) and local failure (LF) was 20 months (95% confidence interval, 14-26) and 26 months (95% confidence interval, 16-36), respectively.
  • On univariate and multivariate analyses, only a mixed histologic type was predictive of inferior DF (p <0.006) and overall survival (p <0.004).
  • [MeSH-major] Mesothelioma / radiotherapy. Mesothelioma / surgery. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Combined Modality Therapy / methods. Confidence Intervals. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674974.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


24. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E: Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2001 Mar;19(3):346-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality management of malignant pleural mesothelioma.
  • OBJECTIVE: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM).
  • METHODS: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy.
  • Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded.
  • RESULTS: Our series included 21 men and 11 women with a median age of 53.5 years (range 40-69).
  • Histologically, there were 26 epithelial, four mixed and two sarcomatous MPM.
  • Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months. CONCLUSIONS:.
  • (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Paclitaxel / administration & dosage. Pneumonectomy / methods. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251277.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Zhang ZG, Hao XS: [Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma]. Zhonghua Zhong Liu Za Zhi; 2004 Oct;26(10):631-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma].
  • OBJECTIVE: To study the methods of diagnosis and treatment of malignant peritoneal mesothelioma.
  • METHODS: The clinical data of 41 patients with malignant peritoneal mesothelioma pathologically confirmed were retrospectively analyzed.
  • The histopathologic types were: epitheloid, fusiform and mixed in 21, 11 and 9 cases.
  • After operation, local abdominal cavity chemotherapeutic instillation was given in 12, systemic chemotherapy in 23 and immunotherapy in 3.
  • CONCLUSION: For malignant peritoneal mesothelioma, the final diagnosis depends on histological examination and the treatment should be surgical-core combined methods.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Laparoscopy. Mesothelioma. Peritoneal Neoplasms
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634530.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Attanoos RL, Gibbs AR: The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology; 2004 Oct;45(4):393-7
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathology associated with therapeutic procedures in malignant mesothelioma.
  • AIMS: To describe iatrogenic pathological lesions in malignant pleural mesothelioma.
  • METHODS AND RESULTS: All cases of malignant pleural mesothelioma confirmed by antemortem pleural biopsy and undergoing post mortem examination over a 7-year period (1995-2001) formed the study group.
  • This comprised 48 malignant pleural mesotheliomas [epithelioid (n = 21), biphasic (n = 14) and sarcomatoid (n = 13)].
  • Twenty-eight of 48 (58%) had received chemical (talc) pleurodesis, 30/48 (63%) palliative localized radiotherapy, 6/48 (13%) chemotherapy, and 14/48 (30%) surgery [12/48 (26%) pleural decortication and 2/48 (4%) pleuropneumonectomy].
  • CONCLUSIONS: Talc pleurodesis induces a marked pseudosarcomatous fibroblastic proliferation which may impart a biphasic pattern to the neoplasm.
  • In more chronic cases, paucicellular fibrosis with a foreign body giant cell reaction is noted.
  • In 6/8 (75%) of these cases, comparative assessment of the locally irradiated subcutaneous chest wall tumour, with background pleural mesothelioma, showed no morphological difference in architectural tumour growth pattern, extent of necrosis, cytological or nuclear pleomorphism, mitotic activity or tumour immunophenotype.
  • In 2/8 (25%) cases the locally irradiated tumour showed prominent bizarre multinucleated tumour giant cells and intense mixed inflammation, a feature not seen in the background (non-irradiated) tumour.
  • All six malignant pleural mesotheliomas receiving chemotherapy appeared refractory to treatment in that chemotherapy did not appear to have any significant effect on the tumour morphology, cytonuclear pleomorphism, mitotic activity, extent of necrosis or immunophenotype.
  • In the 12 decortication specimens and two pleuropneumonectomy resections, post mortem examination identified evidence of residual malignant mesothelioma of similar morphological subtype and immunophenotype to the resected tumour.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy. Pleurodesis. Radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Iatrogenic Disease. Talc / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15469478.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


27. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F, Baas P: Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest; 2001 Oct;120(4):1167-74
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
  • OBJECTIVE: To determine the optimal administered dose of meta-tetrahydroxyphenylchlorin (mTHPC) for intraoperative photodynamic therapy (IPDT) in resected malignant pleural mesothelioma (MPM).
  • The primary objective of this combination treatment was to improve local tumor control.
  • Epithelial mesotheliomas were found in 17 patients, a sarcomatous mesothelioma was found in 1 patient, and mixed epithelial sarcomatous mesotheliomas were found in 10 patients.
  • The real-time fluence rate measurements were performed using four isotropic detectors in the chest cavity to calculate the total light dose.
  • Three patients died in the perioperative period, and one death was directly related to photodynamic therapy.
  • Real-time dosimetry identified 12 patients in whom additional illumination had to be given to the diaphragmatic sinuses, which were unavoidably shielded during integral illumination.
  • The median survival time for all 28 patients was 10 months.
  • Local tumor control, 9 months after treatment, was achieved in 13 of the 26 patients treated with IPDT.
  • CONCLUSION: IPDT using mTHPC, combined with a pleuropneumonectomy, resulted in local control of disease in 50% of the treated cases.
  • The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use.
  • [MeSH-major] Intraoperative Care. Mesothelioma / surgery. Photochemotherapy. Pleural Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Mesoporphyrins / administration & dosage. Mesoporphyrins / adverse effects. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2002 Nov;122(5):1866-7; author reply 1867 [12426299.001]
  • (PMID = 11591556.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; FU21S769PF / temoporfin
  •  go-up   go-down


28. Gulmez I, Kart L, Buyukoglan H, Er O, Balkanli S, Ozesmi M: Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J; 2004 May-Jun;11(4):287-90
Hazardous Substances Data Bank. Erionite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.
  • BACKGROUND: Malignant mesothelioma (MM) is a fatal neoplasm which frequently results from exposure to asbestos or erionite.
  • Their clinical and radiological features, as well as the therapy, were retrospectively evaluated.
  • Pleural effusion (92.4%) was the most common chest x-ray finding, whereas pleural effusion (60.8%), pleural nodules (34.7%) and pleural thickening (34.7%) were the most common computed tomography findings in pleural MM patients.
  • The histological subtypes of MM were determined as epithelial in 60 patients (89.5%), sarcomatous in four patients (5.9%) and mixed in three patients (4.4%).
  • Thirty-five patients (52.2%) were administered chemotherapy, and follow-up data were available for 22 patients.
  • [MeSH-major] Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Environmental Exposure. Female. Humans. Male. Middle Aged. Pleural Effusion / etiology. Tomography, X-Ray Computed. Turkey / epidemiology. Zeolites / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can Respir J. 2004 May-Jun;11(4):273-4 [15254607.001]
  • (PMID = 15254610.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 12510-42-8 / erionite; 1318-02-1 / Zeolites; 1332-21-4 / Asbestos
  •  go-up   go-down


29. Pagan V, Cappelli R, Busetto A, Fontana P, Zaccaria A: [Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study]. Chir Ital; 2003 Jan-Feb;55(1):13-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].
  • [Transliterated title] Pleuro-pneumonectomia, RT e CT per mesotelioma pleurico. Uno studio prospettico.
  • Though associated with substantially prolonged survival, the favourable results of Sugarbaker's trimodality treatment for malignant pleural mesothelioma are controversial and have yet to be extensively reproduced.
  • The aim was to evaluate the prospective medium-term (3-year) reproducibility of the results of trimodality treatment in a significant group of patients staged using the international IMIG classification.
  • Forty-three patients with malignant pleural mesothelioma were candidates for extended pleuropneumonectomy, followed by chemo- and radiotherapy.
  • At thoracotomy, 33 of the 43 surgical candidates underwent extended pleuropneumonectomy and 71% of the 30 evaluable operated patients completed the scheduled course of adjuvant chemotherapy.
  • At 3 years the overall survival of the 30 evaluable patients was 30% and the disease-free survival rate was 25%, with a prevalence of epithelial pI and pII IMIG stages.
  • Survival was less favourable for stage pIII and for mixed tumours.
  • This series confirms the reproducibility of trimodality treatment for malignant pleural mesothelioma.
  • The treatment is associated with prolonged survival in the case of early-stage tumours and has an acceptable complication rate.
  • Early diagnosis, accurate staging, preoperative induction and better local monitoring are avenues to be explored when seeking to achieve curability of malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy. Pneumonectomy / methods
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12633032.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR: Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer; 2001 Feb-Mar;31(2-3):311-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
  • PURPOSE: The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530).
  • Eligibility included a performance status of 0-2 by CALGB criteria, and no prior chemotherapy.
  • Nine patients had epithelial cell type and eight had mixed or sarcomatoid cell types.
  • Eight patients had stable disease, seven developed progressive disease, and two were not evaluable for tumor response.
  • CONCLUSION: No antitumor activity was observed for single-agent gemcitabine in patients with malignant mesothelioma in this multicenter phase II study.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Deoxycytidine / pharmacology. Mesothelioma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11165412.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


31. Otterson GA, Herndon JE 2nd, Watson D, Green MR, Kindler HL, Cancer and Leukemia Group B: Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer; 2004 May;44(2):251-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
  • PURPOSE: The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807).
  • PATIENTS AND METHODS: Between November 15, 2000 and August 31, 2001, 27 patients with mesothelioma were enrolled in this study.
  • Cycles were repeated every 21 days with restaging performed every two cycles and therapy continuing for up to six cycles.
  • One patient withdrew from the study prior to receiving therapy and is removed from further analysis.
  • Eligibility criteria included no prior treatment, PS 0-1 by CALGB criteria and histologically documented mesothelioma.
  • PATIENT CHARACTERISTICS: gender; male 19 (73%), female seven; median age 70 (range 40-81); histology: epithelial 15 (58%), mixed eight (31%), unclassified three; site of origin pleura, 25 (96%); weight loss in previous six months of more than 10% in seven (27%), symptoms longer than six months in five (19%).
  • Median survival and failure free survival were 4.9 (95% CI 4-10.8) and 2.4 (95% CI 1.5-4.2) months respectively with a one-year survival of 23% (95% CI 11-49%).
  • One patient died of treatment related toxicity during cycle one.
  • CONCLUSION: The antitumor activity of capecitabine is insufficient to warrant further exploration in patients with malignant mesothelioma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Capecitabine. Disease-Free Survival. Female. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084390.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 08025; United States / NCI NIH HHS / CA / CA 12046; United States / NCI NIH HHS / CA / CA 16450; United States / NCI NIH HHS / CA / CA 21060; United States / NCI NIH HHS / CA / CA 31946; United States / NCI NIH HHS / CA / CA 31983; United States / NCI NIH HHS / CA / CA 32291; United States / NCI NIH HHS / CA / CA 33601; United States / NCI NIH HHS / CA / CA 35421; United States / NCI NIH HHS / CA / CA 41287; United States / NCI NIH HHS / CA / CA 45418; United States / NCI NIH HHS / CA / CA 45808; United States / NCI NIH HHS / CA / CA 47577; United States / NCI NIH HHS / CA / CA 47642; United States / NCI NIH HHS / CA / CA 77406; United States / NCI NIH HHS / CA / CA 77440; United States / NCI NIH HHS / CA / CA 77658
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Moran CA, Albores-Saavedra J, Suster S: Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases. Histopathology; 2008 Jun;52(7):824-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To present eight cases of primary diffuse peritoneal malignant mesothelioma in children <15 years old, with a discussion of the pitfalls of this diagnosis in the paediatric age group.
  • Histologically, seven cases corresponded to epithelioid mesotheliomas and one case displayed biphasic (epithelioid and spindle) cellular proliferation.
  • Three patients were treated by chemotherapy.
  • On clinical follow-up, four patients with epithelioid mesotheliomas were alive and well from 12 to 18 months after initial diagnosis; one patient with a mixed (biphasic epithelioid/sarcomatoid) mesothelioma died of tumour 24 months after diagnosis.
  • CONCLUSIONS: Peritoneal malignant mesothelioma in children is a rare condition that can introduce difficulties in histopathological diagnosis.
  • [MeSH-major] Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18494612.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / CAM 5.2 antigen; 0 / Calbindin 2; 0 / Keratin-5; 0 / Keratin-6; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


33. Somer RA, Sherman E, Langer CJ: Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer; 2008 Mar;9(2):102-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
  • BACKGROUND: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non-small-cell lung cancer (NSCLC), median survival ranged from 53 weeks to 76 weeks.
  • Sudden life-threatening hemoptysis occurred in 6 of 66 patients receiving chemotherapy and bevacizumab; 4 episodes were fatal, all in patients with squamous cell histology.
  • Squamous histology and bevacizumab therapy were the only factors associated with life-threatening hemorrhage.
  • ECOG 4599 (Eastern Cooperative Oncology Group 4599), a randomized phase III trial of paclitaxel and carboplatin with or without bevacizumab ultimately excluded patients with squamous histology as well as brain metastases, ongoing therapeutic anticoagulation/nonsteroidal anti-inflammatory drugs, antecedent hemoptysis, and performance status (PS) of 2.
  • RESULTS: Forty-five patients had histology that made them ineligible (8 mesothelioma, 6 small-cell, 5 mixed histology, and 26 non-lung cancers).
  • Of the remaining 149 patients, 33 had received chemotherapy previously.
  • Of 82 ineligible patients, 21 (25.6%) had PS > or = 2, 20 (24.3%) had central nervous system (CNS) metastases, 11 (13.4%) had squamous histology, 9 (10.9%) had therapeutic anticoagulation, and 21 (25.6%) had > or = 2 criteria (11 PS > or = 2/squamous histology; 3 PS > or = 2/CNS involvement; 2 PS > or = 2/anticoagulation, 2 CNS metastasis/anticoagulation, 2 PS > or = 2/squamous histology/anticoagulation, 1 PS > or = 2/squamous histology/CNS metastasis).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials, Phase III as Topic. Eligibility Determination. Lung Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Carboplatin / administration & dosage. Humans. Multicenter Studies as Topic. Paclitaxel / administration & dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501096.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


34. Kawamata O, Kondu Y, Murata T, Uetsuka H, Uda M, Nakai H, Ohta T: [Malignant pleural mesothelioma]. Kyobu Geka; 2007 Jan;60(1):31-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma].
  • Malignant pleural mesothelioma carries a poor prognosis, for which no standard therapy has been established.
  • We report 15 cases of malignant pleural mesothelioma experienced since 2000 focusing on their clinical features.
  • Histology of the pleural biopsy specimen showed epithelial mesothelioma in 8 patients, biphasic mesothelioma in 3, sarcomatous mesothelioma in 2 and desmoplastic malignant mesothelioma (DMM) in 2.
  • Twelve patients received chemotherapy.
  • In addition to 2 of these 3 patients, 2 underwent extrapleural pneumonectomy (EPP) without adjuvant treatment.
  • Remaining 1 received palliative treatment only.
  • The longest survival time with chemotherapy is 41 months in a surviving patient with epithelial mesothelioma and that with EPP is 25 months in a surviving patient with DMM.
  • The 2-year survival rate of the 14 patients was 44.4% and the median survival time in patients with epithelial mesothelioma was 30.6 months.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249535.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement